Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Sebia is a world-leading specialized diagnostics company, developing, manufacturing, and commercializing innovative electrophoresis tests and automated systems. Their focus is on in-vitro diagnostic (IVD) solutions for screening and monitoring various diseases, primarily in oncology (Multiple Myeloma), metabolic disorders like diabetes, as well as hemoglobinopathies and rare pathologies. Sebia's technology supports clinicians in making accurate diagnoses and therapeutic decisions, thereby improving patient outcomes. The company has a strong global presence, serving laboratories and healthcare professionals in over 120 countries.
Global corporate management, research and development, primary manufacturing, and international operations coordination for diagnostic solutions.
State-of-the-art facilities within a dedicated technology park, housing advanced R&D laboratories, automated manufacturing lines for diagnostic equipment and reagents, and global logistics operations.
A culture focused on scientific innovation, precision, and quality in medical diagnostics. Emphasizes collaboration between R&D, manufacturing, and commercial teams, with a strong commitment to patient outcomes and regulatory compliance.
The nerve center for Sebia's global operations, product development pipeline, and manufacturing excellence, crucial for maintaining its leadership in specialized clinical diagnostics.
Sebia operates globally with a direct presence through subsidiaries in key markets and an extensive network of over 120 distributors worldwide. Functions supported globally include sales and marketing, customer service and technical support, logistics and distribution, research collaborations, and regulatory affairs to ensure its diagnostic instruments and reagents reach clinical laboratories and hospitals across Europe, North America, Asia-Pacific, Latin America, the Middle East, and Africa.
Parc Technologique de Lisses, 2 rue Léonard de Vinci
Lisses
Essonne, Île-de-France
France
Address: 1700 Spat Center Parkway, Suite 400, Norcross, GA 30093, USA
To drive growth, provide localized customer and technical support, and manage commercial operations for Sebia's advanced diagnostic solutions in the key North American healthcare market.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Sebia' leadership includes:
Sebia has been backed by several prominent investors over the years, including:
No major publicly announced executive hires or departures at the top C-suite level have been identified for Sebia in the last 12 months. The leadership team appears stable following its acquisition.
Discover the tools Sebia uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Sebia commonly utilizes email formats combining the employee's first initial and last name, or occasionally the full first name and last name separated by a dot, followed by '@sebia.com'. Variations might exist based on legacy systems, department, or region.
f.last@sebia.com or first.last@sebia.com
Format
j.doe@sebia.com
Example
75%
Success rate
Sebia Official Website • December 21, 2023
Sebia has launched the Hydrashift 2/4 daratumumab assay, a new IVD test designed to mitigate the daratumumab-mediated interference on immunofixation electrophoresis. This development helps clinicians accurately monitor M-protein for multiple myeloma patients treated with DARZALEX®....more
Sebia Official Website • June 1, 2023
Sebia received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HYDRAGEL IF/sCALD assay. This assay aids in the diagnosis and monitoring of multiple myeloma and other plasma cell dyscrasias by enabling the simultaneous detection and quantification of serum free light chains with immunoglobulin isotypes....more
CVC Capital Partners • October 27, 2022
CVC Capital Partners Fund VIII and Téthys Invest SAS today announced that they have successfully completed the acquisition of a majority stake in Sebia, a global leader in diagnostic testing, from Astorg and Montagu....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Sebia, are just a search away.